Julie Philley, MD

Julie Philley, MD

Chair of the Department of Medicine
Chief of Pulmonary and Critical Care
UT Health North Campus Tyler
The University of Texas Health Sciences Center
Houston, Texas

Related Videos

What are the diagnostic challenges associated with MAC lung disease, the latency period between symptom onset and diagnosis, the disease burden as we understand it; and finally, the geographical distribution of this infection in the United States? Video

What are the diagnostic challenges associated with MAC lung disease, the latency period between symptom onset and diagnosis, the disease burden as we understand it; and finally, the geographical distribution of this infection in the United States?

Based on the current IDSA/ATS guidelines and recent trials, including CONVERT, what do you see as the most important advances in our understanding of NTM pulmonary disease, in particular, with respect to refractory MAC lung disease? Video

Based on the current IDSA/ATS guidelines and recent trials, including CONVERT, what do you see as the most important advances in our understanding of NTM pulmonary disease, in particular, with respect to refractory MAC lung disease?

What is your approach to MAC lung disease patients who fail to microbially convert despite intensive oral anti-infective therapy? Video

What is your approach to MAC lung disease patients who fail to microbially convert despite intensive oral anti-infective therapy?

Are there any postulated strategies for preventing NTM pulmonary disease? Video

Are there any postulated strategies for preventing NTM pulmonary disease?

When should the clinician suspect antimicrobial resistance in the setting of MAC lung disease? How is this confirmed? Video

When should the clinician suspect antimicrobial resistance in the setting of MAC lung disease? How is this confirmed?

How have the results of the CONVERT trial and other studies, and the mechanistic/penetration features of this formulation, influenced your decision-making as it regards selecting an amikacin-based formulation for treating MAC lung disease? Video

How have the results of the CONVERT trial and other studies, and the mechanistic/penetration features of this formulation, influenced your decision-making as it regards selecting an amikacin-based formulation for treating MAC lung disease?

Once the decision is made to deploy amikacin in a patient with refractory MAC lung disease, what do we know about the problematic/toxicity/adherence and side effect pitfalls of IV amikacin, based on results of the CONVERT trial? Video

Once the decision is made to deploy amikacin in a patient with refractory MAC lung disease, what do we know about the problematic/toxicity/adherence and side effect pitfalls of IV amikacin, based on results of the CONVERT trial?

What are the triggers and/or ATS/IDSA guidelines that would prompt you use amikacin for MAC lung disease, in either an IV or liposome aerosol suspension formulation? What is the role, based on the CONVERT trial, for the inhalation suspension? Video

What are the triggers and/or ATS/IDSA guidelines that would prompt you use amikacin for MAC lung disease, in either an IV or liposome aerosol suspension formulation? What is the role, based on the CONVERT trial, for the inhalation suspension?

How frequently should microbiological sampling-whether by sputum or bronchoscopy—be performed in patients with MAC culture positivity who are being treated with antimicrobial therapy? Video

How frequently should microbiological sampling-whether by sputum or bronchoscopy—be performed in patients with MAC culture positivity who are being treated with antimicrobial therapy?